Comment on “Randomization Tests to Address Disruptions in Clinical Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions”
- 23 October 2024
- journal article
- editorial
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 16 (4) , 417-422
Abstract
No abstract availableAll Related Versions
This publication has 23 references indexed in Scilit:
- Targeted Learning: Toward a Future Informed by Real-World EvidenceStatistics in Biopharmaceutical Research, 2023
- Developing a Targeted Learning-Based Statistical Analysis PlanStatistics in Biopharmaceutical Research, 2022
- Estimands and their Estimators for Clinical Trials Impacted by the COVID-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial DisruptionsStatistics in Biopharmaceutical Research, 2022
- The Current Landscape in Biostatistics of Real-World Data and Evidence: Causal Inference Frameworks for Study Design and AnalysisStatistics in Biopharmaceutical Research, 2021
- Discussion of “Randomization: The forgotten component of the randomized clinical trial”Statistics in Medicine, 2018
- RejoinderStatistics in Medicine, 2018
- Targeted Learning in Data Science2018
- Targeted Learning2011
- Causality2009
- A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effectMathematical Modelling, 1986